1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment.
Saved in:
| Title: | 1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment. |
|---|---|
| Authors: | Brose, M.S.1 (AUTHOR), Krajewska, J.A.2 (AUTHOR), Vaisman, F.3 (AUTHOR), Hoff, A.O.4 (AUTHOR), Hitre, E.5 (AUTHOR), Oliver, J.6 (AUTHOR), Williamson, D.S.7 (AUTHOR), Berry, N.8 (AUTHOR), Capdevila Castillon, J.9 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1297-S1298. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159078492 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Brose%2C+M%2ES%2E%22">Brose, M.S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krajewska%2C+J%2EA%2E%22">Krajewska, J.A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vaisman%2C+F%2E%22">Vaisman, F.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hoff%2C+A%2EO%2E%22">Hoff, A.O.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hitre%2C+E%2E%22">Hitre, E.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Oliver%2C+J%2E%22">Oliver, J.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Williamson%2C+D%2ES%2E%22">Williamson, D.S.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Berry%2C+N%2E%22">Berry, N.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Capdevila+Castillon%2C+J%2E%22">Capdevila Castillon, J.</searchLink><relatesTo>9</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 7, Vol. 33, pS1297-S1298. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159078492 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.07.1733 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S1297 Titles: – TitleFull: 1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Brose, M.S. – PersonEntity: Name: NameFull: Krajewska, J.A. – PersonEntity: Name: NameFull: Vaisman, F. – PersonEntity: Name: NameFull: Hoff, A.O. – PersonEntity: Name: NameFull: Hitre, E. – PersonEntity: Name: NameFull: Oliver, J. – PersonEntity: Name: NameFull: Williamson, D.S. – PersonEntity: Name: NameFull: Berry, N. – PersonEntity: Name: NameFull: Capdevila Castillon, J. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2022 Supplement 7 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
